Cipla: M&A positioning, new US regime are key wild cards

Anubhav Sahu • November 04, 2024 / 08:51 IST

The management is primarily focusing on Indian assets which can bring synergy, followed by US assets. Cipla’s continued investment in US subsidiary InvaGen would de-risk the business model from a compliance point of view.

Cipla released better-than-expected Q2 numbers earlier this week.

To read the full story,

Subscribe to Moneycontrol PRO

Ad-free Experience
Access Exclusive Stories
Weekly Investment Ideas
Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Cipla: M&A positioning, new US regime are key wild cards

The management is primarily focusing on Indian assets which can bring synergy, followed by US assets. Cipla’s continued investment in US subsidiary InvaGen would de-risk the business model from a compliance point of view.

What Do You Get